Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update

Another gust of wind behind Lumos Diagnostics' shares today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is jumping 9% into the green today, tipping 95 cents a share before settling back to around 91 cents apiece.

Lumos shares are on the move after the company announced positive readouts from a study concerning its FebriDx diagnostic test.

Here's what we know.

What did Lumos Diagnostics announce today?

The Australian producer of point-of-care diagnostic technologies revealed that its FebriDx diagnostic test was advocated in a prestigious health journal.

The FebriDx is a revolutionary blood test that helps distinguish between viral and bacterial sources of infection. This ultimately helps improve decision making when prescribing antibiotics.

The Journal of Health Economics and Outcomes Research (JHEOR) published a study that concluded using FebriDx "to guide antibiotic treatment for patients presenting with acute respiratory infections (ARIs)" could potentially lead to an annual saving of up to $2.5 billion for the US healthcare system.

Considering the US spent more than US$11,500 per person on healthcare in 2019, according to the US Centre for Medicare and Medicaid Services (CMS), this comes in at a saving of $7.60 per person, or 0.07%.

The authors of the article, Avalon Health Economics, compared 2 scenarios that looked at antibiotic prescription and adverse reactions.

One scenario involved the inclusion of FebriDx compared to a "control" scenario without FebriDx's diagnostic tool.

This is what led researchers to believe an annual $2.5 billion in costs savings could be achieved.

Curiously, estimates suggest "around half of the antibiotics prescribed for ARI's in outpatient settings are medically unnecessary", according to the company's announcement.

Plus, costs associated with these reactions are estimated to be between US$1,156/visit and US$14,678/event for ED visits and hospitalisations respectively.

Lumos intends to make a dent in these numbers with its FebriDx test and, now with additional literature supporting its case, it is one step closer to making it happen.

Lumos Diagnostics share price snapshot

The Lumos Diagnostics share price is swimming in a sea of red and has been since listing back in July. It's given shareholders a loss of 24% since this time, extending its slide in the past week 1.5%

These results have lagged the benchmark S&P/ASX 200 Index (ASX: XJO) over this time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

Why Boss Energy, Emeco, Mineral Resources, and Plenti shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Share Gainers

3 ASX 300 shares going gangbusters on Wednesday

Investors are bidding up these three ASX 300 shares today. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a huge Tuesday for ASX shares, with the index resetting its record high.

Read more »

Woman holding gold bar and cheering.
Gold

Why are ASX gold shares rebounding today?

ASX investors are going for gold today.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

Why Meteoric Resources, Resolute Mining, Sonic Healthcare, and TechnologyOne shares are roaring higher

Let's see why investors are getting excited about these shares on Tuesday.

Read more »

Two kids in superhero capes.
Small Cap Shares

Guess which 2 ASX small-cap shares just rocketed 50%+ on big news!

Investors are sending these two ASX small-cap stocks through the roof on Tuesday.

Read more »